Johnson & Johnson CDR (CAD Hedged)

Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.

Legend Biotech will present nine abstracts on CARVYKTI (ciltacabtagene autoleucel) at the 67th ASH Annual Meeting, including two oral presentations demonstrating long-term progression-free survival benefits and improved immune fitness with earlier treatment use.

Kimberly-Clark has agreed to acquire Tylenol maker Kenvue for approximately $48.7 billion in a cash and stock deal that will create a major consumer health company.

Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA seeking approval of STELARA (ustekinumab) for treating children two years and older with moderately to severely active ulcerative colitis.

The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.

Johnson & Johnson's nipocalimab, a first-in-class FcRn blocker, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in disease activity scores at Week 24 versus placebo.

Abivax shares soared over 850% following positive Phase III data in ulcerative colitis, creating an "Abivax effect" that has reshaped market dynamics and reignited investor confidence in European biotech.

Johnson & Johnson's bispecific antibody Rybrevant demonstrated a 45% objective response rate in previously treated head and neck squamous cell cancer patients, doubling the response rates of current standard treatments.

Johnson & Johnson's subcutaneous amivantamab demonstrated a 45% overall response rate in 38 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma who had progressed on checkpoint inhibitors and platinum-based chemotherapy.

Johnson & Johnson is reportedly considering a complete acquisition of partner Protagonist Therapeutics, following years of successful collaboration on the first-in-class oral peptide icotrokinra for immune-mediated diseases.